EHA Press Releases
[Vilnius, March 10, 2017] Patients suffering from rare blood disorders will benefit from networks of excellence across the European Member States.
At the third conference on European Reference Networks (ERNs) yesterday in Vilnius, Lithuania, EuroBloodNet was officially awarded as one of the recently approved ERNs.
EHA is an active member of the Alliance for Biomedical Research in Europe (BioMed Alliance), in which Europe’s leading medical societies have joined forces to represent the interests of over 400,000 researchers and health professionals.
Brussels/Salamanca, January 9, 2017. The Innovative Medicines Initiative (IMI) has approved HARMONY, a project that aims to foster better access and care for patients with various hematologic malignancies (HM) with the use of big data. The project is made up of 51 partners from 11 European countries, including 7 pharmaceutical companies.
Salamanca, January 19, 2017. Attended by 150 participants from 18 countries the HARMONY project successfully kicked off with a two-day meeting on January 16 and 17.
HARMONY is a European Network of Excellence that captures, integrates, analyses and seeks to harmonize Big Data on various hematological malignancies. The Big Data platform that will be developed is foreseen to enable the rapid definition of promising treatment strategies for individual patients.
EHA is entering the next phase of its Hematology Awareness Campaign this fall. Face-to-face meetings will be conducted with EU institutions and other relevant stakeholders in Brussels, to raise awareness in hematology, increase the visibility of EHA, advocate key EHA positions, contribute to important policy debates and build relationships and alliances.
October 12, 2016, The Hague – Seventeen promising young researchers in clinical research will benefit from a 9-month long unique training and mentoring experience focused on clinical research in Europe through the Clinical Research Training in Hematology (CRTH).
Two studies funded by EHA and published in the medical journal Lancet Haematology by a team of researchers from Oxford University and King’s College found that the economic burden of blood disorders (malignant and non-malignant) across the European Union, Iceland, Norway and Switzerland amounts to €23 billion per year.
The 21st Congress of the European Hematology Association ( June 9-12, 2016) was abuzz with networking between over 10.000 participants who travelled from all over the world to Copenhagen. The EHA Congress combined sessions and a diverse range of topics around Hematology highlighting state-of-the-art clinical practice, recent advances, new data and views from different stakeholders and international organizations. A hot topic this year were the European Reference Networks.
July 22, 2016 - The Hague, The economic burden of blood disorders across the European Union, Iceland, Norway and Switzerland amounts to €23 billion per year. This is the conclusion of two papers published in The Lancet Haematology by the Health Economics Research Centre of the University of Oxford.
Blood disorders represent a myriad of diseases including anemias, coagulation disorders (e.g. thrombosis), bleeding disorders (e.g. hemophilia) and blood cancers (e.g. leukemia, multiple myeloma, lymphoma). In Europe, blood disorders affect around 80 million people.
The total cost of blood disorders consists of healthcare expenditure (€15.6 billion), productivity loss due to illness and mortality (€5.6 billion), and the costs of informal care (€1.6 billion). The latter amount is based on hours of unpaid care provided to people suffering from blood disorders, such as by family or friends. 28% of healthcare costs pertain to medications (€4.3 billion).
PRESS RELEASE - COPENHAGEN, JUNE 11, 2016
EMBARGO TILL JUNE 11, 2016, 08:30 AM CEST
SGN-CD33A Combined with Hypomethylating Therapy Produces High Remission Rates among Older Patients with AML
Acute myeloid leukemia (AML) is an aggressive form of blood cancer in which the majority of cases express CD33 on the surface of the leukemia cells. AML is challenging to treat in older patients since intensive chemotherapy is poorly tolerated, and standard therapies, such as the hypomethylating agents (HMAs) azacitidine and decitabine, yield modest response rates. Data are presented from an ongoing phase 1 trial evaluating vadastuximab talirine (SGN-CD33A; 33A) in combination with standard therapies (azacitidine, decitabine) in older AML patients who have declined intensive frontline therapy. 33A is an antibody-drug conjugate (ADC) targeted to CD33, comprising a novel antibody system stably linked to a highly potent cell-killing agent. CD33 is expressed on leukemic blasts in nearly all AML patients and expression is generally consistent regardless of age, risk factors, or disease characteristics.
Thus far, 53 AML patients with median age of 75 years have been treated with this combination. Of 49 efficacy-evaluable patients treated with 33A combined with either azacitidine or decitabine, the composite complete remission rate (CR+CRi) was 73 percent, which compares favorably with historical studies of HMA monotherapy in this population. The 30- and 60-day mortality rates were two and eight percent, respectively. The most common Grade 3 or higher treatment-emergent adverse events occurring in 20 percent or more of patients were febrile neutropenia, thrombocytopenia, anemia and neutropenia. The combination of 33A and HMAs was well-tolerated and yielded encouraging response rates in older AML patients.
Presenter: Dr Amir Fathi
Affiliation: Massachusetts General Hospital Cancer Center, Boston, USA
Topic: SGN-CD33A IN COMBINATION WITH HYPOMETHYLATING AGENTS: A NOVEL, WELL-TOLERATED REGIMEN WITH HIGH REMISSION RATE IN OLDER PATIENTS WITH AML
Abstract S503 will be presented by Amir Fathi on Saturday, June 11, 16:30 - 16:45 in Hall A3.
About the EHA Annual Congress
Hematology is a specialty that covers everything to do with blood: its origin in the bone marrow, diseases of blood and their treatments. The latest data on research and developments will be presented. The topics range from stem cell physiology and development, to leukemia, lymphoma, myeloma - diagnosis and treatment; red blood cells -, white blood cells- and platelet disorders; thrombosis and bleeding disorders.
EHA Executive Office
Ineke van der Beek, Jon Tarifa
Mobile: +31(0)6 2011 1055